BACKGROUND: Alisertib (MLN8237) is an investigational, oral, selective Aurora A kinase inhibitor. Aurora A contains two functional single nucleotide polymorphisms (SNPs; codon 31 [F/I] and codon 57 [V/I]) that lead to functional changes. This study investigated the prognostic and predictive significance of these SNPs. METHODS: This study evaluated associations between Aurora A SNPs and overall survival (OS) in The Cancer Genome Atlas (TCGA) database. The Aurora A SNPs were also evaluated as predictive biomarkers for clinical outcomes to alisertib in two phase 2 studies (NCT01045421 and NCT01091428). Aurora A SNP genotyping was obtained from 85 patients with advanced solid tumors receiving single-agent alisertib and 122 patients with advanced recurrent ovarian cancer treated with alisertib plus weekly paclitaxel (n=62) or paclitaxel alone (n=60). Whole blood was collected prior to treatment and genotypes were analyzed by PCR. FINDINGS: TCGA data suggested prognostic significance for codon 57 SNP; solid tumor patients with VV and VI alleles had significantly reduced OS versus those with II alleles (HR 1.9 [VI] and 1.8 [VV]; p<0.0001). In NCT01045421, patients carrying the VV alleles at codon 57 (n=53, 62%) had significantly longer progression-free survival (PFS) than patients carrying IV or II alleles (n=32, 38%; HR 0.5; p=0.0195). In NCT01091428, patients with the VV alleles at codon 57 who received alisertib plus paclitaxel (n=47, 39%) had a trend towards improved PFS (7.5months) vs paclitaxel alone (n=32, 26%; 3.8months; HR 0.618; p=0.0593). In the paclitaxel alone arm, patients with the VV alleles had reduced PFS vs modified intent-to-treat (mITT) patients (3.8 vs 5.1months), consistent with the TCGA study identifying the VV alleles as a poor prognostic biomarker. No significant associations were identified for codon 31 SNP from the same data set. INTERPRETATION: These findings suggest that Aurora A SNP at codon 57 may predict disease outcome and response to alisertib in patients with solid tumors. Further investigation is warranted.

Abramson Cancer Center of the University of Pennsylvania Philadelphia PA USA

Centre Oscar Lambret Lille France

Department of Gynecologic Oncology University of Colorado School of Medicine Aurora CO USA

Department of Medical Oncology Dana Farber Cancer Institute Boston MA USA

Department of Medical Oncology Thomas Jefferson University Hospital Philadelphia PA USA

Department of Oncology and Chemotherapy L Rydygiera District Hospital Torun Poland

Department of Oncology Palacky University Medical School and Teaching Hospital Olomouc Czech Republic

Gynecologic Oncology Program Dana Farber Cancer Institute Boston MA USA

Millennium Pharmaceuticals Inc Cambridge MA USA

Sarah Cannon Research Institute at HealthONE Denver CO USA

The University of Texas MD Anderson Cancer Center Houston TX USA

UNC Lineberger Comprehensive Cancer Center Chapel Hill NC USA

EBioMedicine. 2017 Nov;25:18-19. doi: 10.1016/j.ebiom.2017.10.026. PubMed

See more in PubMed

Barr A.R., Gergely F. Aurora-A: the maker and breaker of spindle poles. J. Cell Sci. 2007;120(Pt. 17):2987–2996. PubMed

Bischoff J.R., Anderson L., Zhu Y. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J. 1998;17(11):3052–3065. PubMed PMC

Cervantes A., Elez E., Roda D. Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors. Clin. Cancer Res. 2012;18(17):4764–4774. PubMed

Chen C.H., Chang A.Y., Li S.H. Suppression of Aurora-A-FLJ10540 signaling axis prohibits the malignant state of head and neck cancer. Mol. Cancer. 2015;14:83. PubMed PMC

Chen J., Li D., Wei C. Aurora-A and p16 polymorphisms contribute to an earlier age at diagnosis of pancreatic cancer in Caucasians. Clin. Cancer Res. 2007;13(10):3100–3104. PubMed PMC

Dai Q., Cai Q.Y., Shu X.O. Synergistic effects of STK15 gene polymorphisms and endogenous estrogen exposure in the risk of breast cancer. Cancer Epidemiol. Biomark. Prev. 2004;13(12):2065–2070. PubMed

Dar A.A., Zaika A., Piazuelo M.B. Frequent overexpression of Aurora Kinase A in upper gastrointestinal adenocarcinomas correlates with potent antiapoptotic functions. Cancer. 2008;112(8):1688–1698. PubMed PMC

Ewart-Toland A., Dai Q., Gao Y.T. Aurora-A/STK15 T + 91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer types. Carcinogenesis. 2005;26(8):1368–1373. PubMed

Friedberg J.W., Mahadevan D., Cebula E. Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. J. Clin. Oncol. 2014;32(1):44–50. PubMed PMC

Goldberg S.L., Fenaux P., Craig M.D. An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes. Leuk. Res. Rep. 2014;3(2):58–61. PubMed PMC

Gorgun G., Calabrese E., Hideshima T. A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood. 2010;115(25):5202–5213. PubMed PMC

Hadley K.E., Hendricks D.T. Use of NQO1 status as a selective biomarker for oesophageal squamous cell carcinomas with greater sensitivity to 17-AAG. BMC Cancer. 2014;14:334–342. PubMed PMC

Hoque A., Carter J., Xia W. Loss of aurora A/STK15/BTAK overexpression correlates with transition of in situ to invasive ductal carcinoma of the breast. Cancer Epidemiol. Biomark. Prev. 2003;12(12):1518–1522. PubMed

Kap E.J., Seibold P., Scherer D. SNPs in transporter and metabolizing genes as predictive markers for oxaliplatin treatment in colorectal cancer patients. Int. J. Cancer. 2016;138(12):2993–3001. PubMed

Kelly K.R., Shea T.C., Goy A. Phase I study of MLN8237-investigational Aurora A kinase inhibitor-in relapsed/refractory multiple myeloma, non-Hodgkin lymphoma and chronic lymphocytic leukemia. Investig. New Drugs. 2014;32(3):489–499. PubMed PMC

Kimura M.T., Mori T., Conroy J. Two functional coding single nucleotide polymorphisms in STK15 (Aurora-A) coordinately increase esophageal cancer risk. Cancer Res. 2005;65(9):3548–3554. PubMed PMC

Manfredi M.G., Ecsedy J.A., Chakravarty A. Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays. Clin. Cancer Res. 2011;17(24):7614–7624. PubMed

Marumoto T., Honda S., Hara T. Aurora-A kinase maintains the fidelity of early and late mitotic events in HeLa cells. J. Biol. Chem. 2003;278(51):51786–51795. PubMed

Matulonis U.A., Sharma S., Ghamande S. Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. Gynecol. Oncol. 2012;127(1):63–69. PubMed

Mazumdar A., Henderson Y.C., El-Naggar A.K., Sen S., Clayman G.L. Aurora kinase A inhibition and paclitaxel as targeted combination therapy for head and neck squamous cell carcinoma. Head Neck. 2009;31(5):625–634. PubMed PMC

Melichar B., Adenis A., Lockhart A.C. Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study. Lancet Oncol. 2015;16(4):395–405. PubMed

Miao X., Sun T., Wang Y., Zhang X., Tan W., Lin D. Functional STK15 Phe31Ile polymorphism is associated with the occurrence and advanced disease status of esophageal squamous cell carcinoma. Cancer Res. 2004;64(8):2680–2683. PubMed

Nikonova A.S., Astsaturov I., Serebriiskii I.G., Dunbrack R.L., Golemis E.A. Aurora A kinase (AURKA) in normal and pathological cell division. Cell. Mol. Life Sci. 2013;70(4):661–687. PubMed PMC

Pan J.Y., Ajani J.A., Gu J. Association of Aurora-A (STK15) kinase polymorphisms with clinical outcome of esophageal cancer treated with preoperative chemoradiation. Cancer. 2012;118(17):4346–4353. PubMed PMC

Sehdev V., Katsha A., Ecsedy J., Zaika A., Belkhiri A., El-Rifai W. The combination of alisertib, an investigational Aurora kinase A inhibitor, and docetaxel promotes cell death and reduces tumor growth in preclinical cell models of upper gastrointestinal adenocarcinomas. Cancer. 2013;119(4):904–914. PubMed PMC

Sun J.M., Yang L.N., Xu H., Chang B., Wang H.Y., Yang G. Inhibition of Aurora A promotes chemosensitivity via inducing cell cycle arrest and apoptosis in cervical cancer cells. Am. J. Cancer Res. 2015;5(3):1133–1145. PubMed PMC

Zhang K., Chen J., Chen D. Aurora-A promotes chemoresistance in hepatocelluar carcinoma by targeting NF-kappaB/microRNA-21/PTEN signaling pathway. Oncotarget. 2014;5(24):12916–12935. PubMed PMC

Zhou N., Singh K., Mir M.C. The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo. Clin. Cancer Res. 2013;19(7):1717–1728. PubMed PMC